Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UWMWG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
wO2023232144A1ADC-6
|
|||||
| Synonyms |
WO2023232144A1ADC-6
Click to Show/Hide
|
|||||
| Organization |
GeneQuantum Healthcare (Suzhou) Co. Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.93
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
WO2023232144A1, ADC-2, Payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
WO2023232144A1, ADC-2, linker
|
Linker Info | ||||
| Conjugate Type |
Site asparaginate random conjugation.
|
|||||
| Combination Type |
LP-6
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | ≈ 0.3 nM | Positive ErbB2/HER2 expression (ErbB2/HER2+++/++) | ||
| Method Description |
Cytotoxicity of ADC-2 to SK-BR-3 cells
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | ≈ 8 nM | Positive ErbB2/HER2 expression (ErbB2/HER2+++/++) | ||
| Method Description |
Cytotoxicity of ADC-2 to NCI-N87 cells
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References